Safety and Feasibility Study of Dapivirine (TMC120) Vaginal Ring in Belgium

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

13 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-07-31

Study Completion Date

2005-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This Phase I trial will assess the feasibility of using a vaginal ring to deliver the candidate microbicide dapivirine (TMC120) for 7 days. The study population will consist of 13 healthy, sexually abstinent women. Safety and tolerability will be assessed through clinical and laboratory assessments. Feasibility of drug delivery will be assessed by measuring dapivirine (TMC120) concentrations in vaginal fluids, vaginal and cervical epithelial tissue, and plasma.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Feasibility Study of a Vaginal Ring for Delivery of TMC120 (Dapivirine)

NCT00700284

HIV Infections

COMPLETED PHASE1

A Safety Study of Dapivirine (TMC120) Vaginal Microbicide Gel in Belgium

NCT00309205

HIV Infections HIV-1

COMPLETED PHASE1/PHASE2

Safety and Pharmacokinetic Trial in Healthy HIV-Negative Women to Assess the Delivery of Dapivirine From a Vaginal Ring

NCT02920827

HIV Infections

COMPLETED PHASE1

A Pharmacokinetic Study of Dapivirine Vaginal Rings in Belgium

NCT00469768

HIV Infections

COMPLETED PHASE1

Study of Dapivirine Vaginal Ring (VR) in Adolescents

NCT02028338

Human Immunodeficiency Virus

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

dapivirine (TMC120) vaginal ring

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Female, age 18-50 years
* Willing and able to provide written informed consent
* HIV-uninfected and otherwise healthy
* Willing to abstain from sexual activity and from use of vaginal products while participating in the study
* Currently using oral contraceptives for pregnancy prevention
* Willing to use oral contraceptives as needed to avoid menstruation while taking part in this study

Exclusion Criteria

* History of allergy to TMC120 or to the constituents of the vaginal ring
* History of diagnosis of and/or treatment for a sexually transmitted disease within the last three months
* History of genital tract surgery within the last month
* Currently pregnant or breastfeeding, or within two months of last pregnancy outcome
* Currently or within one month of participating in any other clinical research study
* Current vulvar or vaginal symptoms / abnormalities that could influence the study results
* Current non-iatrogenic pelvic/colposcopic exam findings involving deep epithelial disruption
* Current diagnosis of any genital infection
* Smoking more than 10 cigarettes / day

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes